2013
Topical Chemotherapy in Cutaneous T-cell Lymphoma: Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides
Lessin S, Duvic M, Guitart J, Pandya A, Strober B, Olsen E, Hull C, Knobler E, Rook A, Kim E, Naylor M, Adelson D, Kimball A, Wood G, Sundram U, Wu H, Kim Y. Topical Chemotherapy in Cutaneous T-cell Lymphoma: Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides. JAMA Dermatology 2013, 149: 25-32. PMID: 23069814, PMCID: PMC3662469, DOI: 10.1001/2013.jamadermatol.541.Peer-Reviewed Original ResearchConceptsIndex Lesion SeverityClinical end pointsMycosis fungoidesResponse rateMechlorethamine gelAdverse eventsMulticenter trialTreatment armsLesion severityDrug-related serious adverse eventsSeverity-Weighted Assessment ToolPrimary clinical end pointCutaneous T-cell lymphomaEnd pointSecondary clinical end pointsIIA mycosis fungoidesSerious adverse eventsSubset of patientsTreatment of patientsSerum drug levelsT-cell lymphomaComposite assessmentCarmustine therapyStudy medicationTopical mechlorethamine
2006
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis
Belsito D, Wilson D, Warshaw E, Fowler J, Ehrlich A, Anderson B, Strober B, Willetts J, Rutledge E. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. Journal Of The American Academy Of Dermatology 2006, 55: 40-46. PMID: 16781290, DOI: 10.1016/j.jaad.2006.03.025.Peer-Reviewed Original ResearchConceptsAllergic contact dermatitisNickel-induced allergic contact dermatitisTacrolimus ointmentAdverse eventsContact dermatitisSymptoms of ACDGlobal assessmentChronic allergic contact dermatitisPhysician global assessmentTacrolimus ointment 0.1Pruritus scoreClinical trialsPruritus reductionDay 8TacrolimusDermatitisInner aspectPatientsOintmentSignsTolerabilityArmSymptomsAgentsTrials